

Looking for Daytrana in stock? Here are practical tools and tips to help you locate the methylphenidate patch at pharmacies near you in 2026.
Let's be upfront: Daytrana (Methylphenidate transdermal patch) is one of the hardest ADHD medications to find right now. The manufacturer, Noven Pharmaceuticals, has discontinued production, and no generic version exists. That means the only Daytrana still out there is leftover inventory — and it's disappearing fast.
But "hard to find" doesn't always mean "gone forever." If you've been prescribed Daytrana and want to exhaust every option before switching medications, this guide will walk you through the most effective strategies for tracking it down.
If you'd like to understand why Daytrana is so hard to find, we have a detailed breakdown in a separate article.
The single most efficient thing you can do is use Medfinder to search for Daytrana availability at pharmacies in your area. Medfinder checks real-time stock information across a network of pharmacies, saving you hours of phone calls.
Here's how to use it:
Because Daytrana has a findability score of just 25 out of 100, results may be limited — but Medfinder is the fastest way to know if anyone near you has it. You can also learn more about how to check if a pharmacy has Daytrana in stock.
Big chain pharmacies like CVS, Walgreens, and Rite Aid tend to stock the most commonly prescribed medications. A niche product like Daytrana — which was always low-volume and high-cost — often fell off their regular ordering lists even before the discontinuation.
Independent pharmacies and specialty pharmacies are more likely to:
When you call, be specific: ask for "Daytrana, the methylphenidate transdermal patch" and specify the strength you need (10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, or 30 mg/9 hr). Ask if they can check their wholesaler's inventory, not just their shelf.
While compounding pharmacies can't replicate the Daytrana patch itself, they may have insights on availability in your area. They're well-connected in the pharmacy community and may know who still has stock.
If you're calling pharmacies directly, timing matters:
If pharmacies in your immediate area don't have Daytrana, consider expanding your search. Some patients have found stock at pharmacies 30, 50, or even 100+ miles away. For a medication this scarce, it may be worth the drive.
Things to keep in mind:
If you've tried everything and still can't locate Daytrana, it's time to have an honest conversation with your prescriber about alternatives. The reality is that Daytrana's supply is nearly exhausted nationwide, and waiting for restocking that may never happen isn't a good strategy for managing your ADHD.
Good alternatives to discuss include:
For a complete comparison, see our guide on alternatives to Daytrana.
If you do find Daytrana in stock, be prepared for the price. Without insurance, Daytrana typically costs between $350 and $500 for a 30-day supply. With limited availability, some pharmacies may not accept discount cards or coupons. Check our guide to saving money on Daytrana for all available options.
We understand how stressful it is to not be able to find a medication that works for you or your child. Daytrana was a unique product, and its loss from the market is genuinely felt by the ADHD community.
Your best bet right now is to use Medfinder to check availability, call independent pharmacies, and have a backup plan with your doctor. The sooner you start exploring alternatives, the smoother the transition will be if Daytrana truly can't be found.
Stay proactive, and don't give up on finding the right ADHD treatment — even if it's not Daytrana.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.